Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Extensive-stage small-cell lung cancer with malignant superior vena cava syndrome

Patient Info: Anonymized, Male, 60s

After superior vena cava stenting, facial and upper-extremity edema improved, he was discharged on hospital day 7, and he lived at home without recurrent SVCS symptoms until death from worsening lung cancer about 2 months later.

PubMed CentralRead more →

Recovery from severe liver injury during Stage III gastric cancer treatment

Patient Info: Anonymized, Male, 70+ | Stage III

At the last follow-up in August 2025, imaging showed no recurrence and his liver function remained normal.

PubMed CentralRead more →

Stage III Colorectal Cancer: John's Survivor Story

Patient Info: John Murray, Male, 50s | Stage III

As of February 2026, John’s latest tests showed no evidence of cancer after Stage III rectal cancer treatment, including chemotherapy, radiation, and laparoscopic surgery with permanent colostomy; close surveillance was planned for 2 years.

Cleveland ClinicRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →

Locally advanced lung adenocarcinoma: neoadjuvant treatment, surgery, and fistula repair

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Three months after reconstruction for postoperative esophagopleural fistula, her nutritional status had improved and esophagogram showed no anastomotic leak; long-term lung cancer control was not reported.

PubMed CentralRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Stephanie's Patient Story

Patient Info: Stephanie, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: ovaries; spine; liver; lung

Stage IV ALK-positive NSCLC is being managed with ALK-directed treatment; follow-up scans were described as improving, but the source does not state complete remission.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Joe Carr

Patient Info: Joe Carr | Stage IV

Metastatic Site: liver, lungs

After about 2.5 years of chemotherapy and radiation, Joe had progression in his liver and lungs and was preparing to move into a clinical trial.

Fight Colorectal CancerRead more →

Stage IV Colorectal Cancer: Phil's Survivor Story

Patient Info: Phil Bosanko, Male, 40s | Stage IV

Metastatic Site: Liver

As of February 2026, Phil was alive and cancer-free nearly 20 years after a Stage IV colon cancer diagnosis with extensive liver metastases.

City of HopeRead more →

Stage IV Colorectal Cancer: Cora's Patient Story

Patient Info: Cora, Female | Stage IV

Metastatic Site: Liver; lungs

As of February 2026, Cora had recurrent Stage IV colorectal cancer with a positive ctDNA test but clear CT imaging after stopping an immunotherapy trial because of toxicity, so ongoing care and monitoring were still needed.

The Patient StoryRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Large-Cell Neuroendocrine Cancer of the Cecum in Familial Adenomatous Polyposis

Patient Info: Anonymized, female

Biomarkers: Pathogenic germline APC mutation; KRAS ; PALB2 mutation; microsatellite stable with intact mismatch-repair proteins

At 18 months after the initial right colectomy, there was no pathologic, clinical, or imaging evidence of recurrence.

PubMed CentralRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Nina's Survivor Story

Patient Info: Nina, Female | Stage IV

Metastatic Site: ovaries; liver

After initial Stage IV bowel cancer with spread to the ovaries and liver, surgery and chemotherapy led to no evidence of disease; she continued with regular checkups and emotional recovery.

The Patient StoryRead more →

Localized male small-cell neuroendocrine breast cancer with complete response

Patient Info: Anonymized, Male, 40s

Biomarkers: Synaptophysin-positive; weak cytokeratin-positive; HER2-negative; Ki-67 greater than 70%; genetic testing not performed

The tumor shrank substantially during neoadjuvant cisplatin/etoposide. Modified radical mastectomy then showed a complete pathologic response and 17 reactive axillary lymph nodes; the patient remained disease-free after 18 months of follow-up.

PubMed CentralRead more →

Stage 4 lung cancer: large tumor managed with targeted care

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS <1%

Metastatic Site: contralateral lymph nodes, supraclavicular lymph…

The patient had a partial response to CheckMate 9LA despite PD-L1 TPS <1%, later progressed after 24 cycles of immunotherapy, received additional chemotherapy, and died in November 20XX+2.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage II Triple-Negative Breast Cancer: Chase's Survivor Story

Patient Info: Chase, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative

As of January 2026, Chase had shown no evidence of cancer for nearly 5 years after Stage IIB triple-negative breast cancer treatment and had completed 3 investigational vaccine injections without significant side effects.

Cleveland ClinicRead more →